GILEAD SCIENCES, INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
GILEAD SCIENCES, INC. (GILD) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $43.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-24
- GILEAD SCIENCES, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $43.00M, a 6.52% decline from fiscal 2024.
- GILEAD SCIENCES, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $46.00M, a 31.43% increase from fiscal 2023.
- GILEAD SCIENCES, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $35.00M, a 1066.67% increase from fiscal 2022.
- GILEAD SCIENCES, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $3.00M, a 92.68% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $43.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $46.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $35.00M 10-K · filed 2026-02-24 | -$35.00M 10-K · filed 2024-02-23 |
| 2022-12-31 | $3.00M 10-K · filed 2025-02-28 | -$3.00M 10-K · filed 2023-02-22 |
| 2021-12-31 | $41.00M 10-K · filed 2024-02-23 | |
| 2020-12-31 | -$82.00M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $105.00M 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |